Skip to main content

Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in pediatric cardiac surgery (FICCS study)


We compared hemostatic outcomes after treatment with fibrinogen concentrate or cryoprecipitate in pediatric cardiac surgery patients with intraoperative bleeding.


This was a single-center, randomized, open-label study. Key inclusion criteria were age <15 years, cardiac surgery involving cardiopulmonary bypass, intraoperative bleeding after neutralization of heparin, and hypofibrinogenemia. Patients received fibrinogen concentrate (60 mg/kg body weight; Haemocomplettan® P) or cryoprecipitate (10 ml/kg body weight). After study medication, allogeneic blood products were administered as required. Blood samples taken immediately before randomization and 1, 24 and 48 hours after study medication were subjected to laboratory and thromboelastometry (ROTEM) coagulation tests.


Sixty-three patients (fibrinogen concentrate: 30; cryoprecipitate: 33) completed the study. The median age was 3 years 5 months and the median weight was 6.7 kg. Median fibrinogen doses were 504 mg (fibrinogen concentrate) and 402 mg (cryoprecipitate). Plasma fibrinogen concentrations increased after study medication and were similar in the two groups. No significant between-group differences were observed in PT, aPTT or platelet count. In both groups, all ROTEM parameters showed significant improvement after study medication, with no clinically relevant between-group differences in any of the EXTEM, INTEM or FIBTEM clotting parameters. Total avoidance of allogeneic blood product transfusion was achieved in 70% of patients in the fibrinogen concentrate group versus 18.2% in the cryoprecipitate group (P < 0.001). The mean bleeding mass was significantly lower in the fibrinogen concentrate group than in the cryoprecipitate group after 30 minutes. The thorax was opened after study medication in zero patients (0%) in the fibrinogen concentrate group and in six patients (18.2%) in the cryoprecipitate group (P = 0.025).


Fibrinogen concentrate raised fibrinogen levels and improved coagulation measures to a similar degree as cryoprecipitate. Bleeding and transfusion of allogeneic blood products were lower in the fibrinogen concentrate group. Fibrinogen concentrate may be a valuable option for controlling bleeding and avoiding transfusion in cardiac surgery.

Author information



Corresponding author

Correspondence to F Galas.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Galas, F., Hajjar, L., Sorensen, B. et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in pediatric cardiac surgery (FICCS study). Crit Care 16, P438 (2012).

Download citation

  • Published:

  • DOI:


  • Fibrinogen
  • Study Medication
  • Plasma Fibrinogen
  • Blood Product Transfusion
  • Fibrinogen Concentrate